Korean J Androl.
2008 Dec;26(4):218-222.
Onset of Action of Phosphodiesterase Type 5 Inhibitors in the Treatment of Erectile Dysfunction
- Affiliations
-
- 1Department of Urology, Seoul National University Boramae Hospital, Seoul, Korea.
- 2Department of Urology, Seoul National University School of Medicine, Seoul, Korea.
- 3Department of Family Medicine, Cheju National University, Jeju, Korea.
- 4Department of Urology, Cheju National University, Jeju, Korea. urohjs@cheju.ac.kr
Abstract
-
PURPOSE: After the market launch of multiple phosphodiesterase type 5 inhibitors (PDE5Is), a considerable amount of information has emerged regarding the efficacy and the time of initiation of these drugs. In clinical situations, however, many patients with erectile dysfunction (ED) have complained about the onset of erection occurring later than expected or desired. We therefore studied the time course for initiating an erection after usage of PDE5Is.
MATERIALS AND METHODS
One hundred forty-one patients who were medicated with PDE5Is > 4 times in the most recent 3 months were included for study. The patients were divided into 3 groups: sildenafil (n=51), vardenafil (n=51), and tadalafil (n=39). The choice of PDE5I was made according to the patient's and/or doctor's preferences. Regardless of the type of drug selected, the patients were recommended to have sexual stimulation 15 minutes after taking the medication.
RESULTS
The onset of action of the 3 drug groups were significantly different (sildenafil, 57.0+/-38.5 min; tadalafil, 79.5+/-50.6 min; and vardenafil, 44.4+/-26.6 min; p<0.05). Psychogenic causes of ED resulted in a shorter PDE5I onset of action than organic causes of ED. Other factors, such as body mass index and international index of erectile function erectile function domain score, were shown not to differ with respect to the onset of action of PED5Is.
CONCLUSION
In clinical situations, patients need more time for the onset of erections after taking PDE5Is. For restoration of a healthy sexual life, patients needs more time to achieve an erection after taking PDE5Is.
Keyword
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Chronic Low Dosing of Phosphodiesterase Type 5 Inhibitor for Erectile Dysfunction
- The risk factors, diagnosis and treatment guideline of erectile dysfunction
- Treatment Strategy for Non-Responders to PDE5 Inhibitors
- Benign Prostatic Hyperplasia and Sexual Dysfunction
- Comparison of the Efficacy, Safety and Patient Preference of the Phosphodiesterase Type 5 Inhibitors for the Patients with Erectile Dysfunction
